Clinical Research

Can Clinical Trials help patients with chemotherapy induced alopecia?

Chemotherapy induced alopecia also known as the (CIA) is a distressing side effect of the treatment which induces hair loss in patients. For many patients, it is an emotionally stressful time as their hair is a part of their image and the way other people look at them when they step outside. One of the main reasons why chemotherapy induces hair loss is because the treatment is meant to kill rapidly growing cells, thus sometimes affecting the cells present in our hair follicles as well. This differs from person to person, wherein some experience only the thinning of hair, whereas some experience no hair fall at all.Owing to the above, Paxman, who are the leading experts in scalp cooling therapies due to chemotherapy induced alopecia, has been granted Investigational Device Exemption (IDE) approval status from the US FDA. Since then, Paxman has announced that they will be conducting multicentric randomized clinical trial for the prevention of cancer induced chemotherapy. The study will be conducted amongst 235 patients across the USA. If the trial is successful, it will be a boon for many people who are known to refuse treatment due to the fear of hair loss. The system is known to be use friendly, cost effective and efficient. It has been accepted by many doctors across other nations, nursing staff and patients as well.

Leave a Reply

Your email address will not be published. Required fields are marked *